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Abstract
Background: The objective of this study was to evaluate angiogenesis according to CD34 antigen
expression in estrogen receptor (ER)-positive and negative breast carcinomas.
Methods:  This study comprised 64 cases of infiltrating ductal carcinoma in postmenopausal
women divided into two groups: Group A: ER-positive, n = 35; and Group B: ER-negative, n = 29.
The anti-CD34 monoclonal antibody was used as a marker for endothelial cells. Microvessel count
was carried out in 10 fields per slide using a 40× objective lens (magnification 400×). Statistical
analysis of the data was performed using Student's t-test (p < 0.05).
Results:  The mean number of vessels stained with the anti-CD34 antibody in the estrogen
receptor-positive and negative tumors was 23.51 ± 1.15 and 40.24 ± 0.42, respectively. The number
of microvessels was significantly greater in the estrogen receptor-negative tumors (p < 0.001).
Conclusion: ER-negative tumors have significantly greater CD34 antigen expression compared to
ER-positive tumors.
Background
There has been growing interest in the important role
played by the estrogen receptor in the clinical care of
patients with breast cancer [1]. Only around 6 – 10% of
normal breast epithelial cells express estrogen receptors
(ER), while around 60% of primary breast cancers are ER-
positive [2,3]. This possibility makes the definition of
estrogen receptor status a routine procedure in the man-
agement of a patient with breast cancer, primarily as a pre-
dictive and then as a prognostic factor [4]. A relatively
better prognosis may be expected in patients whose
tumors express estrogen receptors compared with tumors
that do not [5,6].
Estrogen, by interacting with ER, plays an important role
not only in the regulation and differentiation of the nor-
mal breast epithelium but also in breast tumorigenesis
[7]. Estrogen deprivation has been shown to result in a
marked reduction in angiogenesis, which returns to pre-
treatment levels following estrogen replacement [8,9].
There is considerable experimental evidence showing that
tumor growth is dependent on angiogenesis; moreover, a
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tumor will not grow to more than 1–2 mm, around 106
cells, nor metastasize if neovascularization from preexist-
ing capillaries fails to occur [10,11].
In general, malignant tumors with poor prognosis were
found to have high microvessel density (MVD) [12]. Sev-
eral papers have shown that the quantification of angio-
genesis by counting blood vessels provides an
independent assessment of prognosis [13]. A correlation
between ER status and microvessel count (MVC) in a
breast tumor would be of great interest, useful not only for
defining prognosis but also for the selection of patients
with initial breast cancer for hormone therapy [7]. Some
authors have reported a reduction in the expression of vas-
cular endothelial growth factor (VEGF) in ER-positive
breast tumors, principally in those with high levels of ER-
alpha [14,15]. Other investigators have found no differ-
ence and others even same an increase in the MVC of ER-
positive compared to ER-negative tumors [16,17]. There-
fore, in view of these controversies, the present study eval-
uated angiogenesis and ER status in biopsy samples from
pretreatment breast carcinomas.
Methods
This study included tumor samples from 64 patients, who
had been postmenopausal for at least two years and who
were receiving care at the Mastology Department of the
Federal University of Piauí. These patients were submitted
to surgical treatment between 2004 and 2006 for estrogen
receptor-positive and negative infiltrating ductal breast
carcinoma. None of these patients had undergone any
prior treatment. The study was approved by the Institu-
tional Review Board of the Federal University of Piauí and
the patients signed an informed consent form prior to
undergoing diagnostic biopsy. The samples were obtained
from incisional biopsy carried out prior to definitive treat-
ment. The biopsy samples were fixed in buffered formalin
and stained with hematoxylin-eosin for confirmation of
the diagnosis of invasive ductal carcinoma. All samples
were then submitted to immunohistochemical analysis to
evaluate estrogen receptor status. Tumors with nuclear
staining that was semiquantitatively classified as high
(>10% immunoreactive cells) were considered positive
[18].
The cases were then divided into two groups: Group A: ER-
positive, n = 35; and Group B: ER-negative, n = 29.
Patients ranged in age from 47 to 82 years (mean 52.40
years) in Group A and from 46 to 88 years (mean 58.38
years) in Group B. The size of the tumors in the two
groups ranged from 2.5 to 5 cm, stage II, mean tumor size
3.36 and 3.26 in groups A and B, respectively. The groups
were considered homogeneous with respect to age and to
the size and histological grade of the tumor (Table 1). For
CD34 antigen immunostaining, specific primary mono-
clonal antibody for CD34 was used (Anti-human Hemat-
opoietic Progenitor Cell, CD34 Class II, Clone QBEnd 10,
Code M 7165, DAKO Corporation, Carpinteria, CA, USA)
at a dilution of 1:25 with bovine serum albumin (BSA).
Antigen retrieval was carried out in a steamer containing
sodium citrate buffer (pH = 6) at 90°C for 30 minutes.
Sections were then incubated overnight with the primary
specific antibody at 4°C. Color was developed using DAB
(3-3' diaminobenzidine, SIGMA code 5637), a chromog-
enic substrate. Liver hemangiomas were used to test posi-
tive and negative controls for the immunohistochemical
reaction.
Microvessel count was performed by two independent
observers, who were blinded with respect to the patients'
identities. A Nikon Eclipse E400 light microscope was
used to count microvessels and was coupled to a color
video camera that transmitted the image to a microcom-
puter and hence to a monitor, counting being performed
with the aid of an image analysis software program
(Imagelab). Initially, the areas with greater microvessel
density were identified at a magnification of 40×. Micro-
vessel count was performed in 10 fields in each of these
areas of highest density (40× objective lens, 10× ocular
lens), total magnification 400×. Units of vessel counts
were identified according to the criteria established by
Weidner et al [19], who described them as a group of
brown-stained endothelial cells, clearly separated from
the adjacent microvessels, tumoral cells and other con-
junctive tissues. The vessel lumen, although usually
Table 1: Characteristics of the patients in the study groups
Age (years) Group A Group B
Mean 52.40 58.38
SE 2.32 2.26
SD 13.75 12.18
P = 0.070: Student's t-test; P = 0.204: Mann-Whitney's non-
parametric test
Tumor size (cm)
Mean 3.36 3.26
SE 0.21 0.22
SD 1.25 1.19
P = 0.746: Student's t-test; P = 0.833: Mann-Whitney's non-
parametric test
Histological grade
n (%) n (%)
1 12 (34.29) 8 (27.59)
2 16 (45.71) 11 (37.93)
3 7 (20.00) 10 (34.48)
total 35 (100.00) 29 (100.00)
P = 0.426: Chi-square test
Group A: ER-positive, n = 35; Group B: ER-negative, n = 29
SD: standard derivation; SE: standard errorInternational Seminars in Surgical Oncology 2007, 4:22 http://www.issoonline.com/content/4/1/22
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present, was not a criterion used to define a microvessel,
and red blood cells were not used to define vessel lumens.
Partially identified vessels that were not completely con-
tained within the fields under analysis were not consid-
ered in the vessel count. In each case, microvessel density
consisted of the mean number of vessels counted in ten
fields.
Student's t-test and the Mann-Whitney non-parametric
test were used to establish homogeneity between the two
groups with respect to age and tumor volume. The Chi-
square test was used to evaluate the difference between the
two groups with respect to histological grade (Table 1).
Student's t-test was used to compare the mean number of
vessels in the two groups (p < 0.05).
Results
Under light microscopy, varying degrees of vascular neo-
formation were found in the two groups. There were
greater concentrations of microvessels stained brown by
the anti-CD34 antibody in the tumor samples from the
estrogen receptor-negative group compared to the estro-
gen receptor-positive tumors (Figures 1 and 2). Quantita-
tive analyses of the microvessels in the 10 fields revealed
a mean vessel count of 23.51 ± 0.72 in the estrogen recep-
tor-positive tumors and 40.24 ± 1.54 in the estrogen
receptor-negative tumors (Table 2). This difference was
statistically significant (p < 0.001). There was excellent
agreement and low interobserver variance between the
two observers for the 64 specimens (R2 = 0.99).
Discussion
The growth and proliferation of tumor cells, as well as
their metastatic dissemination, have been shown to be
preceded and facilitated by the formation of new blood
vessels from preexisting capillaries [11]. Angiogenesis has
been considered an independent prognostic factor [8];
therefore, its assessment may provide additional informa-
tion on the biological profile of the tumor, and may have
applications in prognostic evaluation and as a therapeutic
target in human breast carcinoma [13,20]. Nevertheless,
although a higher density of microvessels is generally
found in malignant breast tumors with the worst progno-
sis and estrogen receptor-negative tumors have a relatively
poorer prognosis, conflicting reports have been published
on the correlation between tumoral angiogenesis and ER
status [5-7,12,15,16].
In the present study, microvessel count in estrogen recep-
tor-negative breast carcinomas of postmenopausal
women was significantly greater compared to estrogen
receptor-positive breast carcinomas. The women in the
two groups were homogenous with respect to age and to
the size and histological grade of the tumor, which made
comparison between the two groups feasible. The tumor
specimens in the present study were obtained from wedge
biopsy; therefore, it is unlikely that the results obtained
simply reflect tumor heterogeneity, which is a recognized
methodological problem [17]. Studies carried out to eval-
uate the effect of tumor heterogeneity in microvessel
count in breast cancer specimens have focused on the use
of core biopsies [17], which contain less tumor volume
than the preoperative wedge biopsies used in this study.
Microphotograph of a histological section of estrogen recep- tor-negative breast carcinoma (patient #8), showing a high  concentration of microvessels stained with anti-CD34 (Orig- inal magnification, 400×) Figure 2
Microphotograph of a histological section of estrogen recep-
tor-negative breast carcinoma (patient #8), showing a high 
concentration of microvessels stained with anti-CD34 (Orig-
inal magnification, 400×).
Microphotograph of a histological section of estrogen recep- tor-positive breast carcinoma (patient #5), showing sparse  vessels stained with anti-CD34 (Original magnification, 400×) Figure 1
Microphotograph of a histological section of estrogen recep-
tor-positive breast carcinoma (patient #5), showing sparse 
vessels stained with anti-CD34 (Original magnification, 
400×).International Seminars in Surgical Oncology 2007, 4:22 http://www.issoonline.com/content/4/1/22
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CD34 was selected from the available markers because it
is a sensitive marker that stains the neoplastic endothe-
lium more strongly than the normal endothelium [21].
The presence of a significantly lower number of vessels in
the ER-positive breast tumors observed in the present
study indicates a correlation between tumor angiogenesis
and estrogen receptor status. Moreover, in an in vivo study
using nude female mice, Ali et al. [15] showed that high
levels of ER-alpha downregulate angiogenic factors VEGF
and integrin alphavbeta3 (αvβ3), leading to inhibition of
tumor angiogenesis.
On the other hand, Erdem et al. [16] failed to show any
difference between mean MVD values in estrogen recep-
tor-positive and negative tumors. The samples in that
study consisted of archival specimens collected around 7–
10 years previously. However, for some investigators,
material kept in storage for a long time may result in loss
of antigenicity for some markers [22]. Likewise, in sam-
ples obtained by core needle biopsy from breast tumors of
158 patients, Vamesu [7] showed that a high microvessel
density was significantly more common in patients with
ER-positive/PR-negative tumors. Nevertheless, the possi-
ble effect of tumor heterogeneity on microvessel counts in
specimens originating from core biopsies should be
emphasized [17] as well as the overexpression of variants
of the subtypes of estrogen receptor that affect the regula-
tion of tumor angiogenesis [23].
Of the multitude of growth factors that regulate angiogen-
esis, VEGF is believed to be the most important, whereas
exon-deleted variants of ER-alpha, such as ERDelta3, a
variant frequently overexpressed in breast cancer, may
exert an undesirable effect, contributing significantly to
VEGF production and thus exacerbating tumor growth in
vivo [23]. Therefore, a better understanding of the correla-
tion between VEGF and the subtypes of estrogen receptors
and their variants in breast cancer, in combination with
their prognostic importance, may lead to the develop-
ment of therapeutic strategies directed against VEGF or its
receptor.
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